Tc 99m arcitumomab

Drug Profile

Tc 99m arcitumomab

Alternative Names: CEA-Scan; ImmuRAID-CEA; ImmuRAID-CEA-Tc-99m; Tc-99m arcitumomab; Technetium Tc 99m arcitumomab

Latest Information Update: 12 Jun 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Immunomedics
  • Class Monoclonal antibodies; Monoclonal antibody diagnostics; Organotechnetium compounds; Radiopharmaceutical diagnostics; Radiopharmaceuticals; Technetium compounds
  • Mechanism of Action Single-photon emission-computed tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Market Withdrawal Colorectal cancer

Most Recent Events

  • 01 Jul 2003 Clinical data from a media release have been added to the adverse events section
  • 15 Jul 2002 Daiichi Pure Chemical obtains a non-exclusive licence to the CEA patents of Immunomedics
  • 13 Jun 2002 Tc 99m arcitumomab licensed to Teva-Tuteur in Latin Amerrica
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top